C4 Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
C4 Therapeutics, Inc. (CCCC) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 118.69 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- C4 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 119.97M shares, a 598.37% increase year-over-year.
- C4 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 17.18M shares, a 50.32% increase year-over-year.
- C4 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 11.43M shares, a 35.02% increase year-over-year.
- C4 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 8.46M shares, a 15.61% increase year-over-year.
- C4 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 117.74M shares, a 785.73% increase from fiscal 2024.
- C4 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 13.29M shares.
- C4 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 5.98M shares, a 11.46% increase from fiscal 2020.
- C4 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 5.37M shares, a 65.87% decline from fiscal 2019.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 118.69M shares 10-Q · filed 2026-08-11 | ||||||
| 2026-03-31 | 119.97M shares 10-Q · filed 2026-05-12 | ||||||
| 2025-12-31 | 117.74M shares 10-K · filed 2026-02-26 | ||||||
| 2025-09-30 | 16.76M shares 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | 17.12M shares 10-Q · filed 2026-08-11 | ||||||
| 2025-03-31 | 17.18M shares 10-Q · filed 2026-05-12 | 13.89M shares 10-Q · filed 2025-05-07 | |||||
| 2024-12-31 | 13.29M shares 10-K · filed 2026-02-26 | ||||||
| 2024-09-30 | 13.29M shares 10-Q · filed 2025-11-06 | 11.85M shares 10-Q · filed 2024-10-31 | |||||
| 2024-06-30 | 13.30M shares 10-Q · filed 2025-08-07 | 11.65M shares 10-Q · filed 2024-08-01 | |||||
| 2024-03-31 | 11.43M shares 10-Q · filed 2025-05-07 | ||||||
| 2023-09-30 | 9.87M shares 10-Q · filed 2024-10-31 | ||||||
| 2023-06-30 | 7.93M shares 10-Q · filed 2024-08-01 | ||||||
| 2023-03-31 | 8.46M shares 10-Q · filed 2024-05-08 | ||||||
| 2022-09-30 | 6.95M shares 10-Q · filed 2023-11-01 | ||||||
| 2022-06-30 | 7.06M shares 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | 7.32M shares 10-Q · filed 2023-05-04 | ||||||
| 2021-12-31 | 5.98M shares 10-K · filed 2022-02-24 | ||||||
| 2021-09-30 | 5.88M shares 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | 6.15M shares 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | 6.29M shares 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | 5.37M shares 10-K · filed 2022-02-24 | ||||||
| 2020-09-30 | 33.05M shares 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | 31.24M shares 10-Q · filed 2021-08-11 | ||||||
| 2020-03-31 | 15.00M shares 10-Q · filed 2021-05-13 | ||||||
| 2019-12-31 | 15.73M shares 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |